GSK3B and Alzheimer disease: This becomes therapeutically relevant in AD, wherein Pin1 and GSK3β may be downregulated under hypoxic or ischemic conditions, allowing cis-HIF-1α to accumulate and contribute to the increased expression of β-secretase 1 and the consequent amyloidogenic APP processing [63,199,200].